

- Systemic sclerosis (scleroderma), treatment of
(*Cont.*):
for renal complications, 1865, 2164
skin care, 2164–2165
vascular therapy, 2164
- Systemic vascular resistance, 1729
calculation and normal values, 1463, 1748t
effect on murmurs, 51e-7
in pregnancy, 45
in sepsis/septic shock, 1755
in shock, 1744, 1748t
- Systems biology, **87e-1**
human disease classification and, 87e-3–4,
87e-4f, 87e-5f, 87e-6f
in medical practice, 6
pathobiology applications of, 87e-3–4
properties of biologic systems, 87e-1–2, 87e-2f
- Systems neuroscience, 444e-12, 465e-3–4
- Systems theory, 12e-1, 12e-1f
- Systolic blood pressure, 1616t, 1622
- Systolic click-murmur syndrome. *See* Mitral valve prolapse
- Systolic failure. *See* Heart failure (HF)
- Systolic murmurs. *See* Heart murmurs
- SYT gene mutations, 119e-1
- T**
- T₃. *See* Triiodothyronine (T₃)
- T₃-resin uptake test, 2288
- T₄. *See* Thyroxine (T₄)
- TABI/2, 145e-6f
- Tabes dorsalis, 1136, 2658f
- Tabun. *See* Nerve agents
- TAC3 gene mutations, 2364t, 2377
- TAC3R gene mutations, 2364t
- Tacaiuma virus, 1308t
- Tâche noire, 1157, 2745
- Tachycardia
atrioventricular nodal reentry, 1479–1480,
1481f
in hypovolemia, 298
in overdose/poisoning, 473e-3
preexcited, 1482, 1483f
supraventricular. *See* Supraventricular tachyarrhythmias
syncope in. *See* Cardiac syncope
treatment of, 1479t
ventricular. *See* Ventricular tachycardia
- Tachycardia-bradycardia syndrome, 146, 1468,
1469
- Tachykinins, 565
- Tachypnea, 1746, 1757
- Tacrine, 473e-10t, 2601
- Tacrolimus
action of, 1829t, 2071
adverse effects of, 1829, 1829t, 2071
hyperkalemia, 310
myopathy, 2218t
nephrotoxicity, 1856t, 1862, 1864, 2071
osteoporosis, 2492
seizures, 1793, 2547t
skin cancer, 388
thrombocytopenic purpura, 729
for atopic dermatitis, 345, 354t
drug interactions of, 246e-3t, 2071
genetic variations in response to, 39t
for IBD, 1961
for immunosuppression
after kidney transplantation, 1829, 1829t
after liver transplantation, 2071
for lupus dermatitis, 2134
metabolism of, 34t, 2071
for myasthenia gravis, 2705
for polymyositis, 2201
for SLE, 2133
therapeutic monitoring of, 2766t
- Tactile fremitus, 1662
- Tadalafil
action of, 324, 325f, 326f
adverse effects of, 328, 329t
characteristics of, 329t
contraindications to, 328, 329t
for erectile dysfunction, 328, 2672
for high-altitude pulmonary edema, 476e-3
for lower urinary tract symptoms, 587
for pulmonary arterial hypertension, 1660,
1660t
for Raynaud's phenomenon, 1649
- Taenia asiatica*, 1430
- Taenia multiceps*, 1435
- Taenia saginata* (beef tapeworm) infection
clinical features of, 1430
diagnosis of, 245e-1, 245e-2t, 245e-5t, 245e-6t,
1430
geographic distribution of, 245e-2t, 1430
life cycle of, 245e-2t, 1430
pathogenesis of, 1430
prevention of, 1430
treatment of, 1430
- Taenia serialis*, 1435
- Taenia solium* (pork tapeworm) infection
clinical features of, 1430–1431. *See also* Cysticercosis
diagnosis of, 245e-1, 245e-2t, 245e-5t, 245e-6t,
1431–1432, 1431t
geographic distribution of, 245e-2t, 1430
life cycle of, 245e-2t, 1430
pathogenesis of, 1430
prevention of, 1432
treatment of, 1432
- Tafamidis, 724
- Tafenoquine, 246e-1t, 246e-13
- TAFI (thrombin-activatable fibrinolysis inhibitor), 744
- Tag SNPs, 442
- Tahyña virus, 1309t, 1315
- Tai chi, 14e-1t
- Tai Forest virus disease, 1323, 1325f, 1326f
- TAK-1, 145e-6f
- Takayasu's arteritis, **2189**
aortic aneurysm in, 1638
aortitis in, 1642
arterial involvement in, 386e-5f, 2189, 2189t
carotid or vertebral artery occlusion in, 2567,
2574
clinical features of, 1642, 2189–2190
definition of, 2189
diagnosis of, 386e-5f, 1642, 2190
epidemiology of, 1642
incidence and prevalence of, 2189
pathogenesis of, 1642, 2189
treatment of, 1642, 2190
- Takotsubo (stress-related) cardiomyopathy, 97,
289e-3
- TALI* gene mutations, 101e-3t
- Talc, intrapleural, 474
- Talc dust, 1690
- Talc embolism, 40e-4
- Tamm-Horsfall protein, 293, 294, 1804, 1854,
1859
- Tamoxifen
action of, 102e-4f, 102e-7, 103e-15
adverse effects of
cataracts, 531, 623
depression, 63
endometrial cancer, 103e-15
hepatotoxicity, 2025
thrombocytopenia, 727t
thromboembolism, 103e-15
tumor lysis syndrome, 1795
uterine cancer, 531, 596, 623
visual loss, 607t
for breast cancer prevention, 29t, 478, 531,
2498–2499
for breast cancer treatment, 102e-7, 103e-15,
528–529, 529t, 530t
drug interactions of, 40, 205e-3
for ductal carcinoma in situ, 531
genetic variations in response to, 39t, 40
for gynecmastia, 585, 2367
metabolism of, 35
for osteoporosis management/prevention,
2498
- Tanapox, 220e-1t, 220e-2
- TandemHeart, 296e-5
- Tangier disease (ABCA1 deficiency), 1443, 2445,
2681
- Tanning, 386, 387, 498, 500
- Tapeworms/tapeworm infections. *See* Cestodes/cestode infections
- TAP (transporters associated with antigen processing) proteins, 372e-19, 373e-3–4
- Tap test, 2748
- Tarantulas, 2748
- TARC (CCL17), 372e-12t, 1674, 1674f
- Tardive dyskinesia, 163, 261, 2624, 2722
- Tardive dystonia, 2624
- Tardive syndromes, 2624
- TARDP* gene mutations, 444e-1, 2603
- Target cells, 81e-1, 81e-4f, 395f
- Target lesion revascularization, 296e-3
- Target of rapamycin (TOR), 94e-5. *See also* mTOR
- Target vessel revascularization, 296e-3
- Target volume, in radiation therapy, 103e-4
- Tartrate-resistant acid phosphatase (TRAP), 426e-4
- Tartrazine, 1671
- Tarui's disease (phosphofructokinase deficiency), 433e-2t, 462e-14, 654t
- Taste buds, 212, 213f, 215
- Taste disorders
diseases and conditions associated with, 215
drug-related, 215
etiology of, 215
evaluation of, 215–216
head injury and, 457e-2
olfactory dysfunction and, 215
treatment of, 216–217
in zinc deficiency, 96e-9
- Taste pore, 212, 213f
- Taste system, 212–214, 213f
- TATA-binding protein, 431t
- Tatagaine virus, 1306t
- tat* gene, 225e-3f, 1219f
- Tat protein, 225e-2
- Tau protein, 172t, 175, 453e-6
- TAVR (transcatheter aortic valve replacement). *See* Aortic valve replacement, transcatheter
- Taxanes. *See also specific drugs*
adverse effects of, 620t, 1798, 2686t
for breast cancer, 529, 530
characteristics of, 103e-12t, 103e-14–15
drug interactions of, 1793
for melanoma, 499
for ovarian cancer, 593
resistance to, 103e-15
for soft tissue sarcoma, 119e-2
- Tax proteins, 214e-5, 214e-7, 225e-2, 225e-3–4
- Tay-Sachs disease, **432e-1**
adult, 432e-1, 432e-3t, 2634t, 2636
“cherry red” spot in eye in, 436e-7f
enzyme deficiency in, 432e-3t
genetic screening for, 432e-1, 443
infantile, 432e-1
juvenile, 432e-1, 432e-3t
- Tazarotene, 348
- TAZ* gene mutations, 1564
- Tazobactam, 933
- TB. *See* Tuberculosis (TB)
- TBG (thyroxine-binding globulin), 2285, 2286,
2286t, 2288
- TBI (traumatic brain injury). *See* Head injury
- TBII (thyrotropin-binding inhibitory immunoglobulin), 2290, 2294
- TBX* gene mutations, 431t
- TCAs. *See* Tricyclic antidepressants (TCAs)
- T cell(s)
age-related reduction in, 94e-4
allogenic, transfer of, 103e-20
antigen recognition by, 372e-18–19,
372e-18f
in asthma, 1673, 1674f
in autoimmune diseases, 372e-23, 377e-1t,
377e-2, 377e-4
autologous, manipulation of, 103e-20
autoreactive, in MS, 2662
central memory, 372e-16
in cord blood, 89e-3–4
cytotoxic. *See* CD8+ T cells